Telomerase peptide vaccination combined with temozolomide: A clinical trial in stage IV melanoma patients

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4568-4580

  Kyte, Jon Amund ^a,b   Gaudernack, Gustav ^b,c   Dueland, Svein ^a   Trachsel, Sissel ^b   Julsrud, Lars ^b   Aamdal, Steinar ^a,c  

^a Department of Oncology   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; GAMMA INTERFERON; GLUTAMYLALANYLARGINYLPROLYLALANYLLEUCYLLEUCYLTHREONYLSERYLARGINYLLEUCYLARGINYLPHENYLALANYLISOLEUCYLPROLYLLYSINE; INTERLEUKIN 10; PEPTIDE VACCINE; TELOMERASE PEPTIDE VACCINE GV 1001; TEMOZOLOMIDE; TERTOMOTIDE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; LYMPHOCYTE PROLIFERATION; MELANOMA; MEMORY CELL; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CYTOKINES; DACARBAZINE; HUMANS; IMMUNOLOGIC MEMORY; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TELOMERASE; TREATMENT OUTCOME; VACCINES, SUBUNIT; YOUNG ADULT;

EID: 79960329487     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0184     Document Type: Article

References (50)

1. Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, et al. A new era in anticancer peptide vaccines. Cancer 2010;116:2071-80.
2. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8:59-73.
3. Huang X, Huang G, Song H, Chen L. Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced-killer cells in a murine lung carcinoma model. Int J Cancer 2010. [Epub ahead of print].
4. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by gliomasecreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 2008;57:123-31. (Pubitemid 350043644)
5. Gonzalez-Aparicio M, Alzuguren P, Mauleon I, Medina-Echeverz J, Hervas-Stubbs S, Mancheno U, et al. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut 2010;60:341-49.
6. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34. (Pubitemid 351264344)
7. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748-59. (Pubitemid 37527210)
8. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66. (Pubitemid 30036349)
9. Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007;12:1114-23. (Pubitemid 350007023)
10. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9. (Pubitemid 29302920)
11. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008;8:167-79. (Pubitemid 351305939)
12. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65:5506-11. (Pubitemid 40911148)
13. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
14. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
15. Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR, et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 2007;67:10546-55. (Pubitemid 350070831)
16. Haining WN, Davies J, Kanzler H, Drury L, Brenn T, Evans J, et al. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res 2008;14:5626-34.
17. Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007;25:2727-34. (Pubitemid 47123180)
18. Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 2004;10:4688-98.
19. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006;55:1553-64. (Pubitemid 44327843)
20. Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 2006;95:1474-82. (Pubitemid 44863349)
21. Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs 2009;18:687-94.
22. Shaw VE, Naisbitt DJ, Costello E, Greenhalf W, Park BK, Neoptolemos JP, et al. Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Rev Vaccines 2010;9:1007-16.
23. Kyte JA, Trachsel S, Risberg B, thor Straten P, Lislerud K, Gaudernack G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol Immunother 2009;58:1609-26.
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
25. Bijker MS, Melief CJ, Offringa R, Van Der Burg SH. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 2007;6:591-603. (Pubitemid 47281301)
26. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
27. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-8. (Pubitemid 40977140)
28. Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006;13:905-18. (Pubitemid 44373791)
29. Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, et al. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother 2007;56:659-75.
30. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 2006;6:329-33.
31. Romagnani S. Human Th17 cells. Arthritis Res Ther 2008;10:206-13.
32. Greten TF, Forner A, Korangy F, N'Kontchou G, Barget N, Ayuso C, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC cancer 2010;10:209.
33. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-7. (Pubitemid 28450038)
34. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003;88:1004-11. (Pubitemid 36560766)
35. Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol 2005;23:4235-6. (Pubitemid 46211332)
36. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004;22:610-6. (Pubitemid 41095063)
37. Kim CH, Woo SJ, Park JS, Kim HS, Park MY, Park SD, et al. Enhanced antitumour immunity by combined use of temozolomide and TATsurvivin pulsed dendritic cells in a murine glioma. Immunology 2007;122:615-22.
38. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 2008;10:98-103. (Pubitemid 351250906)
39. Kim TG, Kim CH, Park JS, Park SD, Kim CK, Chung DS, et al. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol 2010;17:143-53.
40. Neyns B, Tosoni A, Hwu WJ, Reardon DA. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer 116;2868-77.
41. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300:337-9. (Pubitemid 36433726)
42. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003;421:852-6. (Pubitemid 36254145)
43. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107:477-84. (Pubitemid 32167994)
44. Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G. Cytotoxic CD4+ and CD8 +T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997;72:784-90. (Pubitemid 27431521)
45. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berendsvan der Meer DM, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008;14:178-87. (Pubitemid 351377994)
46. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, Whittle HC, et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 2008;38:350-63.
47. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006;107:4781-9. (Pubitemid 43882629)
48. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13:843-50. (Pubitemid 47038186)
49. Kokhaei P, Palma M, Hansson L, Osterborg A, Mellstedt H, Choudhury A. Telomerase (hTERT 611-626) serves as a tumor antigen in Bcell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp Hematol 2007;35:297-304. (Pubitemid 46135817)
50. Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005;23:9001-7. (Pubitemid 46211484)